AngioDynamics ANGO has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment ...

A downtrend has been apparent in AngioDynamics (ANGO) lately. While the stock has lost 6.1% over the past week, it could ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

Per the WARN notice, AngioDynamics cited “contract loss” as the reason for the upcoming layoffs of nonunion employees at its ...

Shares of AngioDynamics (NASDAQ: ANGO) were crashing 17.1% lower as of 10:43 a.m. ET on Thursday. The steep sell-off came after the medical technology company announced its fiscal 2025 first-quarter ...

CEO Jim Clemmer highlighted strong Q3 performance with total revenue reaching $72 million, reflecting over 9% year-over-year growth. MedTech revenue grew by 22%, with continued success across ...

Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment “The publication of the PRESERVE study in European ...

AngioDynamics (ANGO) has been on a downward spiral lately with significant selling pressure. After declining 25% over the past four weeks, the stock looks well positioned for a trend reversal as it is ...

AngioDynamics has announced it has received FDA clearance for a new peripherally inserted central catheter, according to a news release. The company’s BioFlo peripherally inserted central catheters ...

On January 6, 2026, AngioDynamics raised its fiscal 2026 net sales guidance to US$312 million–US$314 million and reported narrower losses on higher quarterly sales, while also disclosing that ...

The medical technology company announced the retirement of CEO Jim Clemmer. This news creates uncertainty for AngioDynamics -- and investors dislike uncertainty. However, the company's business ...